Publisher
Springer Berlin Heidelberg
Reference43 articles.
1. Bartha R, Williamson PC, Drost DJ, Malla A, Carr TJ, Cortese L, Canaran G, Rylett RJ, Neufeld RWJ (1997) Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 54: 959–965
2. Bartoszyk GD, Roos C, Ziegler H (1996) 5-HT1A receptors are not involved in clozapine’s lack of cataleptogenic potential. Neuropharmacol 11: 1645–1646
3. Bylund DB, Eikenberg DC, Hieble J, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo Jr RR, Trendelenburg U (1994) International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46: 121–136
4. Casey DE (1989) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacol 99: S47 - S53
5. Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481–483